Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease

被引:45
作者
Brooks, Alenka J.
Begg, Evan J.
Zhang, Mei
Frampton, Chris M.
Barclay, Murray L.
机构
[1] Christchurch Hosp, Dept Med & Clin Pharmacol, Christchurch, New Zealand
[2] Univ Otago, Dept Med, Christchurch, New Zealand
[3] Christchurch Hosp, Dept Pathol, Christchurch, New Zealand
[4] Christchurch Hosp, Dept Gastroenterol, Christchurch, New Zealand
关键词
methotrexate; methotrexate polyglutamates; inflammatory bowel disease; pharmacokinetics; therapeutic drug monitoring;
D O I
10.1097/FTD.0b013e31811f39bb
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Methotrexate (MTX) use in inflammatory bowel disease (11313) is complicated by unpredictable efficacy and toxicity. In rheumatoid arthritis, total and individual red blood cell MTX polyglutamates (RBC MTXGlu(1-5)) correlate with disease activity and possibly toxicity, and therefore may be useful in guiding treatment. It is unclear if this applies in IBD. The aim of this pilot study was to measure total and individual RBC MTXGlu(1-5) concentrations in patients with IBD to see if these relate to efficacy and adverse effects. RBC MTXGlu(1-5) concentrations were measured on three occasions in 18 patients with IBD receiving MTX at a constant dose for 3 or more months. The intrapatient variability, expressed as the coefficient of variation, of RBC MTXGIu(1-5) concentrations at steady state was determined, and disease activity and adverse effects were assessed against concentrations. The intrapatient coefficients of variation of individual MTXGlu(1-5) varied from 12% to 27%. In Crohn's disease, higher RBC MTXGlu(4&5) concentrations correlated with worse disease activity (r(2) = 0.42 and 0.53, respectively P <= 0.03). RBC MTXGlu(5) concentrations were higher in patients experiencing at least one adverse effect as a result of MTX compared with those without adverse effects (mean, 26.7 versus 11.1 nmol/8 x 10(12) RBCs; mean difference, 15.6; 95% confidence interval, 3.5-27.7; P = 0.04). Similar trends were observed for RBC MTXGlu(4). Furthermore, patients who specifically experienced gastrointestinal adverse effects had higher RBC MTXGlu4&5 concentrations than patients without (P = 0.03 and 0.04, respectively). In summary, RBC MTXGlu(1-5) concentrations can be measured accurately with low intrapatient variation. Unexpectedly, RBC MTXGlu4&5 concentrations correlated inversely with efficacy in Crohn's disease. RBC MTXGlu4&5 concentrations were higher in patients experiencing adverse effects. These findings suggest that RBC MTXGlu(1-5) concentration monitoring may be of value in IBD and could assist with planning of larger studies.
引用
收藏
页码:619 / 625
页数:7
相关论文
共 43 条
[11]   THE ANTIINFLAMMATORY MECHANISM OF METHOTREXATE - INCREASED ADENOSINE RELEASE AT INFLAMED SITES DIMINISHES LEUKOCYTE ACCUMULATION IN AN IN-VIVO MODEL OF INFLAMMATION [J].
CRONSTEIN, BN ;
NAIME, D ;
OSTAD, E .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2675-2682
[12]  
DERJIKS LJJ, 2006, ALIMENT PHARM THERAP, V24, P715
[13]   Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis [J].
Dervieux, T ;
Furst, D ;
Lein, DO ;
Capps, R ;
Smith, K ;
Walsh, M ;
Kremer, J .
ARTHRITIS AND RHEUMATISM, 2004, 50 (09) :2766-2774
[14]   Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study [J].
Dervieux, T ;
Furst, D ;
Lein, DO ;
Capps, R ;
Smith, K ;
Caldwell, J ;
Kremer, J .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) :1180-1185
[15]   HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis [J].
Dervieux, T ;
Lein, DO ;
Marcelletti, J ;
Pischel, K ;
Smith, K ;
Walsh, M ;
Richerson, R .
CLINICAL CHEMISTRY, 2003, 49 (10) :1632-1641
[16]  
Egan LJ, 1999, ALIMENT PHARM THER, V13, P1597
[17]   A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease [J].
Feagan, BG ;
Fedorak, RN ;
Irvine, EJ ;
Wild, G ;
Sutherland, L ;
Steinhart, AH ;
Greenberg, GR ;
Koval, J ;
Wong, CJ ;
Hopkins, M ;
Hanauer, SB ;
McDonald, JWD .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (22) :1627-1632
[18]   Methotrexate in inflammatory bowel disease [J].
Feagan, BG ;
Alfadhli, A .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2004, 33 (02) :407-+
[19]   METHOTREXATE FOR THE TREATMENT OF CROHNS-DISEASE [J].
FEAGAN, BG ;
ROCHON, J ;
FEDORAK, RN ;
IRVINE, EJ ;
WILD, G ;
SUTHERLAND, L ;
STEINHART, AH ;
GREENBERG, GR ;
GILLIES, R ;
HOPKINS, M ;
HANAUER, SB ;
MCDONALD, JWD .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (05) :292-297
[20]   The efficacy of methotrexate for maintaining remission in inflammatory bowel disease [J].
Fraser, AG ;
Morton, D ;
McGovern, D ;
Travis, S ;
Jewell, DP .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (04) :693-697